Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays
Broad range of selectivity possesses serious limitation for the development of matrix metalloproteinase-2 (MMP-2) inhibitors for clinical purposes. To develop potent and selective MMP-2 inhibitors, initially multiple molecular modeling techniques were adopted for robust design. Predictive and validated regression models (2D and 3D QSAR and ligand-based pharmacophore mapping studies) were utilized for estimating the potency whereas classification models (Bayesian and recursive partitioning analyses) were used for determining the selectivity of MMP-2 inhibitors over MMP-9. Bayesian model fingerprints were used to design selective lead molecule which was modified using structure-based de novo technique. A series of designed molecules were prepared and screened initially for inhibitions of MMP-2 and MMP-9, respectively, as these are designed followed by other MMPs to observe the broader selectivity. The best active MMP-2 inhibitor had IC50 value of 24nM whereas the best selective inhibitor (IC50=51nM) showed at least 4 times selectivity to MMP-2 against all tested MMPs. Active derivatives were non-cytotoxic against human lung carcinoma cell line-A549. At non-cytotoxic concentrations, these inhibitors reduced intracellular MMP-2 expression up to 78% and also exhibited satisfactory anti-migration and anti-invasive properties against A549 cells. Some of these active compounds may be used as adjuvant therapeutic agents in lung cancer after detailed study..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Bioorganic & medicinal chemistry - 24(2016), 18, Seite 4291-4309 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Adhikari, Nilanjan [VerfasserIn] |
|---|
| Links: |
|---|
| RVK: |
|---|
| doi: |
10.1016/j.bmc.2016.07.023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1986063836 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1986063836 | ||
| 003 | DE-627 | ||
| 005 | 20230714233229.0 | ||
| 007 | tu | ||
| 008 | 161202s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bmc.2016.07.023 |2 doi | |
| 028 | 5 | 2 | |a PQ20170206 |
| 035 | |a (DE-627)OLC1986063836 | ||
| 035 | |a (DE-599)GBVOLC1986063836 | ||
| 035 | |a (PRQ)c1256-25011c6a2e3810bb7aec8a69180dd28e1fb07e748e0030f8882eb7274971b0890 | ||
| 035 | |a (KEY)0240099520160000024001804291robustdesignofsomeselectivematrixmetalloproteinase | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |a 610 |q DE-600 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a VA 2619 |q AVZ |2 rvk | ||
| 100 | 1 | |a Adhikari, Nilanjan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Broad range of selectivity possesses serious limitation for the development of matrix metalloproteinase-2 (MMP-2) inhibitors for clinical purposes. To develop potent and selective MMP-2 inhibitors, initially multiple molecular modeling techniques were adopted for robust design. Predictive and validated regression models (2D and 3D QSAR and ligand-based pharmacophore mapping studies) were utilized for estimating the potency whereas classification models (Bayesian and recursive partitioning analyses) were used for determining the selectivity of MMP-2 inhibitors over MMP-9. Bayesian model fingerprints were used to design selective lead molecule which was modified using structure-based de novo technique. A series of designed molecules were prepared and screened initially for inhibitions of MMP-2 and MMP-9, respectively, as these are designed followed by other MMPs to observe the broader selectivity. The best active MMP-2 inhibitor had IC50 value of 24nM whereas the best selective inhibitor (IC50=51nM) showed at least 4 times selectivity to MMP-2 against all tested MMPs. Active derivatives were non-cytotoxic against human lung carcinoma cell line-A549. At non-cytotoxic concentrations, these inhibitors reduced intracellular MMP-2 expression up to 78% and also exhibited satisfactory anti-migration and anti-invasive properties against A549 cells. Some of these active compounds may be used as adjuvant therapeutic agents in lung cancer after detailed study. | ||
| 540 | |a Nutzungsrecht: Copyright © 2016 Elsevier Ltd. All rights reserved. | ||
| 700 | 1 | |a Halder, Amit K |4 oth | |
| 700 | 1 | |a Mallick, Sumana |4 oth | |
| 700 | 1 | |a Saha, Achintya |4 oth | |
| 700 | 1 | |a Saha, Kishna D |4 oth | |
| 700 | 1 | |a Jha, Tarun |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Bioorganic & medicinal chemistry |d Amsterdam [u.a.] : Elsevier, 1993 |g 24(2016), 18, Seite 4291-4309 |w (DE-627)171175506 |w (DE-600)1161284-8 |w (DE-576)038869047 |x 0968-0896 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2016 |g number:18 |g pages:4291-4309 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.bmc.2016.07.023 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/27452283 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-CHE | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_4305 | ||
| 936 | r | v | |a VA 2619 |
| 951 | |a AR | ||
| 952 | |d 24 |j 2016 |e 18 |h 4291-4309 | ||